Reference
Dolph M, et al. Cost-Effectiveness of Once Weekly Selinexor-Bortezomib-Dexamethasone (XVD) in Previously Treated Multiple Myeloma (MM). 26th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN82, 17 May 2021. Available from: URL: https://www.ispor.org/heor-resources/presentations-database/presentation/intl2021-3339/109925
Rights and permissions
About this article
Cite this article
Selinexor, bortezomib, dexamethasone cost effective in previously treated multiple myeloma. PharmacoEcon Outcomes News 880, 27 (2021). https://doi.org/10.1007/s40274-021-7785-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-021-7785-x